imaging studies, obtained along the course of the disease, were compared to the neuropathologic findings. Results: FTDP-17T cases were associated with symmetric frontotemporal atrophy. Behavioral changes constituted the predominant clinical presentation. Conversely, an asymmetric degenerative process was seen in all 3 PGRN cases, who presented with either corticobasal syndrome (A9D) or frontotemporal dementia and language deterioration (IVS6-2A 1 G and R493X). Conclusion: Neuroimaging data, in the early disease stage of FTDP-17, may offer the possibility of an early differentiation of FTDP-17T and FTDP-17U phenotypes, independent of the genetic analysis. To determine whether neuroimaging studies may allow an in vivo early differentiation between FTDP-17T and FTDP-17U. Methods: We studied 25 individuals affected with FTDP-17T associated with either the exon 10+3 (24 subjects) or the G335S (1 subject) MAPT mutation, as well as 3 FTDP-17U individuals, who were carriers of the A9D, IVS6-2A 1 G or R493X PGRN mutation. Neuro-
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Neurodegenerative Dis 2008; 5:215-217 216 spread deposition of hyperphosphorylated tau protein in the central nervous system of affected individuals (FTDP-17T) [5] . On the contrary, the neuropathology of cases with PGRN mutations is characterized by the presence of tau-negative, ubiquitin-and TDP-43-positive neuronal and glial inclusions in the frontotemporal cortex and subcortical white matter, striatum and dentate gyrus of affected individuals (FTDP-17U) [6] . In spite of these differences, FTDP-17T and FTDP-17U share a largely overlapping range of clinical presentations that limits the possibility of antemortem differential diagnosis between the two syndromes to the genetic analysis only. Here we review clinical, neuroimaging and neuropathological findings obtained from a subset of FTDP-17 patients. Neuroimaging data are considered in order to evaluate the hypothesis that phenotypic differences may allow an in vivo early differentiation between the FTDP-17T and FTDP-17U syndromes, prior to genetic or postmortem investigation.
Materials and Methods
We have reviewed clinical and, when available, imaging and neuropathological data from 28 individuals affected with FTDP-17: 24 carriers of the exon 10+3 MAPT mutation, 1 carrier of the G335S MAPT mutation, and 3 carriers of distinct PGRN mutations (A9D, IVS6-2A 1 G and R493X). MRI scans were available for 8 exon 10+3 MAPT mutation carriers, the carrier of the G335S MAPT mutation and the 3 PGRN mutation carriers. PGRN mutation carriers also underwent PET scan. Histology and immunohistochemistry (phosphorylated tau, ubiquitin, and TDP43) were carried out in 14 exon 10+3 MAPT mutation carriers, the G335S MAPT mutation carrier and the 3 PGRN mutation carriers.
Results
Among individuals with the exon 10+3 MAPT mutation for whom this information was available, 81% presented with behavioral, personality and executive changes; 14% had parkinsonism as early major complaint, and 5% presented with isolated memory loss. Neuroimaging disclosed predominant frontotemporal atrophy, with a symmetric pattern in virtually all cases. Neuropathological examination revealed findings consistent with the diagnosis of 'multiple system tauopathy with presenile dementia' [7] . The carrier of the G335S MAPT mutation presented with social withdrawal and personality changes at age 22. Later on in the disease course, he developed dysexecutive symptoms, parkinsonism and ideomotor apraxia. Neuroimaging examination in vivo and postmortem neuropathological examination revealed severe atrophy of the frontal and temporal lobes, in a symmetric fashion. Abundant neuronal and glial tau pathology was observed with tau immunohistochemistry. Frontotemporal dementia and progressive nonfluent aphasia characterized the clinical presentation of the 2 individuals harboring the IVS6-2A 1 G or the R493X PGRN mutations. On the contrary, the third PGRN mutation carrier (A9D) presented with corticobasal syndrome with features of left-sided hemineglect and alien-hand syndrome. Interestingly, an asymmetric degenerative process was observed in all 3 PGRN mutation carriers both at neuroimaging and neuropathological examination. Predominant atrophy and hypometabolism in the left cerebral hemisphere was observed in the IVS6-2A 1 G and R493X PGRN mutation carriers. Mirrored findings were observed in the A9D PGRN mutation carrier, who displayed predominant atrophy and hypometabolism of the right cerebral hemisphere. Cases with PGRN mutation matched pathological criteria for 'frontotemporal lobar degeneration with ubiquitin-and TDP-43-positive inclusions' and displayed neuronal intra nuclear inclusions [6] . Additional information on these cases is provided elsewhere [8] [9] [10] [11] .
Discussion
This review of FTDP-17 cases suggests the possibility of a different pattern of involvement of the cerebral hemispheres in the FTDP-17T and FTDP-17U cases. While virtually all subjects with FTDP-17T presented a symmetric pattern of frontotemporal lobar degeneration both at neuroimaging and neuropathological examination, all of the FTDP-17U cases were characterized by a striking lateralization of the degenerative process, with significantly severer involvement of one cerebral hemisphere compared to the contralateral one. The higher degree of asymmetry characterizing the degenerative process of the cerebrum in FTDP-17U cases may constitute the anatomopathologic base for the identification of more topographically restricted patterns of cognitive dysfunction in FTDP-17U cases compared to what is observed in FTDP-17T cases. Specifically, a severer degree of atrophy of the dominant hemisphere may have led to a more clinically significant impairment of language in the early disease course of the subjects with the IVS6-2A 1 G and R493X PGRN mutations. A severer involvement of the nondominant hemisphere may have resulted in the clinical observation of signs, such as contralateral hemine-glect or alien-hand syndrome observed in the carrier of the A9D PGRN mutation [10] . These data are consistent with those of several reports of FTDP-17 associated with PGRN mutation [12] [13] [14] [15] . In one of these studies, the authors emphasize the contrast between the markedly asymmetric distribution of pathological changes in a carrier of the Q486X PGRN mutation and the relatively symmetric atrophic process observed in a series of FTDP-17T individuals, carriers of the exon 10+16 MAPT mutation [13] . Although these data are not based on the study of a large series of cases, they raise the possibility that an asymmetric involvement of the cerebrum might constitute a more likely event in FTDP-17U than in FTDP-17T. This multidisciplinary approach provides valuable insights into the natural history of these disorders and tests the possibility of an early clinical differentiation of FTDP-17T and FTDP-17U phenotypes, independent of the genetic investigation.
